1 / 21

Thomas J. Kim, MD, MPH Epidemic Intelligence Service Officer

Medical Surveillance for Flavorings-Related Lung Disease in Flavor Manufacturing Workers: The CA Department of Public Health Experience. Thomas J. Kim, MD, MPH Epidemic Intelligence Service Officer California Department of Public Health Occupational Health Branch.

elata
Download Presentation

Thomas J. Kim, MD, MPH Epidemic Intelligence Service Officer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Medical Surveillance for Flavorings-Related Lung Disease in Flavor Manufacturing Workers: The CA Department of Public Health Experience Thomas J. Kim, MD, MPH Epidemic Intelligence Service Officer California Department of Public Health Occupational Health Branch www.dhs.ca.gov/ohb/flavorings.htm

  2. Identification of Bronchiolitis Obliterans (BO) in California • 29 y/o Male in August 2004 • 40 y/o Female in April 2007 • Powder-flavor mixers • Non-smokers, no prior chemical exposure • Symptoms after 2 – 5 yrs exposure • BO diagnosis based on history, fixed airways obstruction and high resolution CT (HRCT) findings

  3. The California Response • Cal/OSHA citations and special order • Diacetyl hazard factsheet • Identification of diacetyl users in CA • Collaboration among • Cal/OSHA • Industry and medical consultant • CA Department of Public Health • Technical assistance from NIOSH

  4. CA Response: Industry Special Emphasis Program • Companies agreed to • Undergo IH assessment • Start a medical surveillance program • Implement exposure controls • Otherwise be subject to compliance inspections • Data obtained from 21 companies • Approximately 530 workers

  5. Goals of Medical Surveillance • Primary • Identify BO at earliest onset • Industry-wide analysis to identify risk factors to guide prevention measures • Secondary • Identify other occupational lung disease related to flavor manufacturing • Improve longitudinal surveillance and spirometry quality in CA occupational health clinics

  6. Surveillance Description • Role of companies • Role of providers • Role of the CA Department of Public Health

  7. Role of Companies • Appropriately identify workers at potential risk and enroll in surveillance • Contract with qualified clinical services • Ensure surveillance occurs at recommended intervals • Train workers • Communicate with health provider, IH, and Cal/OSHA on necessary interventions

  8. Role of Providers • Implement recommended guidelines • Administer questionnaire and spirometry • Educate workers at each visit • Maintain good spirometry quality • Initiate further evaluation in workers with abnormal screening • Protect workers through duty modifications or removal • Workplace visits and ensure good communication with companies

  9. Role of CDPH • Serve as a consultant to local providers • Develop surveillance guidelines • Provide central review of spirometry quality • Analyze industry wide surveillance data • Work with Cal/OSHA and NIOSH to prevent disease via control measures

  10. Worker status determination Occupational Health Provider Feedback & consultation to provider Further medical evaluation; Duty modification; Cal/OSHA evaluation; Workplace intervention CDPH: Spirometry quality review; surveillance data interpreted Surveillance Overview Questionnaire Spirometry

  11. Abnormal Spirometry Evaluation Spirometry & Questionnaire Abnormal spirometry Normal Complete PFTs Fixed obstruction Non-fixed Obstruction Restriction Post-hire or worsening control asthma Asthma: stable HRCT

  12. Abnormal Spirometry Evaluation Spirometry & Questionnaire Abnormal spirometry Normal Complete PFTs Fixed obstruction Non-fixed Obstruction Restriction Post-hire or worsening control asthma Asthma: stable HRCT

  13. FEV1 and FEV1/FVC • Obstructive pattern: • FEV1/FVC ≤ LLN • Interval FEV1 decline > 15% from baseline • FEV1/FVC alone • Provides increased sensitivity • For the elderly • And young healthy males • FEV1/FVC • >70% • LLN (90% NHANES predicted) per ATS

  14. 6 Month Interval >15 % decline Advantage of Using Longitudinal Decline in FEV1 Predicted FEV1

  15. Abnormal Spirometry Evaluation Spirometry & Questionnaire Abnormal spirometry Normal Complete PFTs Fixed obstruction Non-fixed Obstruction Restriction Post-hire or worsening control asthma Asthma: stable HRCT

  16. Bronchiolitis Obliterans Case • Obstructive pattern on spirometry • Fixed obstruction on pre/post bronchodilation spirometry • On High Resolution Chest CT (HRCT) • Mosaic pattern of attenuation • Air trapping on expiratory views • Cylindrical bronchiectasis • others

  17. Abnormal Spirometry Evaluation: Asthma Spirometry & Questionnaire Abnormal spirometry Normal Complete PFTs Fixed obstruction Non-fixed Obstruction Restriction Post-hire or worsening control asthma Asthma: stable HRCT

  18. Concurrent Lung Conditions: Asthma • Communicate with PMD • Workplace hazard education • Higher threshold for suspicion • Further evaluation warranted • Newly diagnosed through surveillance • Any post-hire onset • Worsening medical control

  19. The Reality of Surveillance from the Public Health Perspective • Non-uniform data collection of symptoms, work information and exposures • Poor timeliness of medical records • Until recently, lack of recommended guidelines • Spirometry quality • Unacceptable curves • Poor repeatability • Improper instrument set up for result printout

  20. Continuing Efforts • Finalize database and analyze questionnaire and spirometry data • Cross-sectional analysis • Longitudinal analysis • Work with providers on improving spirometry quality • Continue to serve in consulting role

  21. CA Dept of Public Health Barbara Materna Janice Prudhomme Egils Kronlins NIOSH Kay Kreiss Nancy Sahakian Kathy Fedan Brian Tift Eva Hzindo Lee Petsonk Consulting Experts Cecile Rose Leslie Israel Paul Enright Phil Harber John Balmes Cal/OSHA Dan Leiner Kelly Howard and other HIs EIS Field Assignments Branch Sheryl Lyss Acknowledgements The findings and conclusions in this presentation have not been formally disseminated by the CDC and should not be construed to represent any agency determination or policy

More Related